Biogen, Inc.
https://www.biogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Biogen, Inc.
New Treatment For Clogged Arteries Gets CMS Pass-Through Payment
Starting 1 July, Medicare beneficiaries with a certain type of cardiovascular disease will be able to receive an innovative treatment covered under their government plans.
Biogen Gives Up On Gosuranemab After No Benefit Seen In Alzheimer's Study
Biogen’s investigational anti-tau antibody gosuranemab has missed its primary efficacy endpoint in a Phase II study in patients with Alzheimer's disease, prompting the end of the trial and termination of the compound’s further clinical development.
Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says
Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.
BIO 2021 Notebook: Biogen CEO On Corporate Responsibility
News and views from day four of the BIO Digital annual meeting include the FDA's plans to use carrots not sticks to improve diversity and reflections on how the pandemic has strengthened biopharmaceutical supply chains.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Biogen Idec
- Convergence Pharmaceuticals Ltd
- Nightstar Therapeutics plc
- Stromedix, Inc.
- Syntonix Pharmaceuticals